Back to Browse Journals » International Journal of Nanomedicine » Volume 7
Degradable polyethylenimine derivate coupled to a bifunctional peptide R13 as a new gene-delivery vector
Authors Liu K, Wang X, Fan W, Zhu Q, Yang J, Gao J, Gao S
Received 4 December 2011
Accepted for publication 5 January 2012
Published 29 February 2012 Volume 2012:7 Pages 1149—1162
DOI https://doi.org/10.2147/IJN.S28819
Review by Single-blind
Peer reviewer comments 3
Kehai Liu1,2,*, Xiaoyu Wang1,*, Wei Fan1, Qing Zhu2, Jingya Yang2, Jing Gao3, Shen Gao1
1Department of Pharmaceutics, Shanghai Hospital, Second Military Medical University, 2Department of Biopharmaceutics, School of Food Science and Technology, Shanghai Ocean University, 3Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai, People's Republic of China
*The first two authors contributed equally to this work
Background: To solve the efficiency versus cytotoxicity and tumor-targeting problems of polyethylenimine (PEI) used as a nonviral gene delivery vector, a degradable PEI derivate coupled to a bifunctional peptide R13 was developed.
Methods: First, we synthesized a degradable PEI derivate by crosslinking low-molecular-weight PEI with pluronic P123, then used tumor-targeting peptide arginine-glycine-aspartate-cysteine (RGDC), in conjunction with the cell-penetrating peptide Tat (49–57), to yield a bifunctional peptide RGDC-Tat (49–57) named R13, which can improve cell selection and increase cellular uptake, and, lastly, adopted R13 to modify the PEI derivates so as to prepare a new polymeric gene vector (P123-PEI-R13). The new gene vector was characterized in terms of its chemical structure and biophysical parameters. We also investigated the specificity, cytotoxicity, and gene transfection efficiency of this vector in avß3-positive human cervical carcinoma Hela cells and murine melanoma B16 cells in vitro.
Results: The vector showed controlled degradation, strong targeting specificity to avß3 receptor, and noncytotoxicity in Hela cells and B16 cells at higher doses, in contrast to PEI 25 KDa. The particle size of P123-PEI-R13/DNA complexes was around 100–250 nm, with proper zeta potential. The nanoparticles can protect plasmid DNA from being digested by DNase I at a concentration of 6 U DNase I/µg DNA. The nanoparticles were resistant to dissociation induced by 50% fetal bovine serum and 600 µg/mL sodium heparin. P123-PEI-R13 also revealed higher transfection efficiency in two cell lines as compared with PEI 25 KDa.
Conclusion: P123-PEI-R13 is a potential candidate as a safe and efficient gene-delivery carrier for gene therapy.
Keywords: nonviral gene vector, polyethylenimine, P123, αvß3, cell-penetrating peptides
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Readers of this article also read:
Causative factors for formation of toxic islet amyloid polypeptide oligomer in type 2 diabetes mellitus
Jeong HR, An SSA
Clinical Interventions in Aging 2015, 10:1873-1879
Published Date: 19 November 2015
Emerging and future therapies for hemophilia
Carr ME, Tortella BJ
Journal of Blood Medicine 2015, 6:245-255
Published Date: 3 September 2015
Mutations in presenilin 2 and its implications in Alzheimer’s disease and other dementia-associated disorders
Cai Y, An SSA, Kim SY
Clinical Interventions in Aging 2015, 10:1163-1172
Published Date: 14 July 2015
A new recombinant factor VIII: from genetics to clinical use
Santagostino E
Drug Design, Development and Therapy 2014, 8:2507-2515
Published Date: 12 December 2014
A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project
Lentz SR, Tandra A, Gut RZ, Cooper DL
Journal of Blood Medicine 2014, 5:1-3
Published Date: 13 January 2014
A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone
Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W
International Journal of Nanomedicine 2012, 7:5719-5724
Published Date: 12 November 2012
Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy
Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS
International Journal of Nanomedicine 2012, 7:4077-4088
Published Date: 27 July 2012
Particle size reduction to the nanometer range: a promising approach to improve buccal absorption of poorly water-soluble drugs
Rao S, Song Y, Peddie F, Evans AM
International Journal of Nanomedicine 2011, 6:1245-1251
Published Date: 20 June 2011
The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia
Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al
International Journal of Nanomedicine 2010, 5:581-591
Published Date: 6 August 2010
Crystallization after intravitreal ganciclovir injection
Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant
Clinical Ophthalmology 2010, 4:709-711
Published Date: 14 July 2010
